Gross sales of $31.08M and net sales of $25.34M
Gross profit of $7.41M or 29% margin
SG&A of $12.28M
Discounts included $1.88M associated with the old Assault, so if it is correct to adjust for this as a one time discount, then gorss margin would be 34%. FitMiss sales of $1M and Arnold off to a good start at $3.7M. Hope those number continue to grow though! I think top line revenue growth was quite strong, but I am dissappointed with margins at 29%. If the above adjustment is realistic, then I would be bullish with 34% margins in their first quarter of controlling distribution. This should only improve and bringing mfg. in house could further improve this. SG&A is certainly high, but $4M of that expense was non-cash. Still in an ok position cash wise (new acquisition dependent).
Will be interested to hear BioZone/Fuse plans tomorrow.
"At the end of Q3 2013, the Company had approximately $5.7 million of cash and cash equivalents, approximately $9.6 million of inventory, approximately $34.4 million in current assets, and no long-term debt. Shareholders' equity at September 30, 2013 increased to $22.7 million as compared to ($9.8 million) at December 31, 2012."